Print

Search Results: Prevention, Detection & Risk (14 results)

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

https://www.facingourrisk.org/research-clinical-trials/study/101/a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

SOROCk [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes among women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes and not the ovaries is to prevent surgically-induced menopause. The study will also examine various patient-reported quality of life outcomes. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer. This concept has never been formally testing in a clinical trial.

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease

Prevention
Screening study for people with a mutation linked to prostate cancer risk

The PATROL (Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for prostate cancer because they carry one or more genes that are known or suspected to increase prostate cancer risk: BRCA2, HOXB13, ATM, BRCA1, MLH1, MSH2, MSH6, PALB2, PMS2, CHEK2, RAD51D, or TP53.

Men at High Genetic Risk for Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests. 

Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/284/testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer

Prevention
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy.

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

Pancreatic Cancer Early Detection for People at High Risk

https://www.facingourrisk.org/research-clinical-trials/study/227/pancreatic-cancer-early-detection-for-people-at-high-risk

Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening

The study will collect clinical information, family history, and samples (blood, saliva or cheek swab) from people and families at risk for pancreatic cancer. Collecting this information and samples will create a resource to drive research necessary for early detection and prevention of pancreatic ductal adenocarcinoma (PDAC).

MRI Screening in Men at High Risk of Developing Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/260/screening-in-men-at-high-risk-of-developing-prostate-cancer

Prevention
Screening using MRI for men at risk of developing prostate cancer

This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.

Testing the Drug Obeticholic Acid for Familial Adenomatous Polyposis

https://www.facingourrisk.org/research-clinical-trials/study/289/testing-the-drug-obeticholic-acid-for-familial-adenomatous-polyposis

Prevention
Prevention study for people with an APC mutation and FAP or AFAP who have polyps in remaining tissue after colectomy surgery

This study is looking at whether obeticholic acid (OCA) is safe and has a beneficial effect on the number of polyps in the small bowel and colon in people with familial adenomatous polyposis (FAP). OCA is a drug similar to a bile acid the body's liver makes. Researchers believe OCA may help keeping cancer from developing. OCA is already FDA approved to treat a type of liver disease. There have been studies showing that OCA decreases inflammation and fibrosis. However, it is not yet known whether OCA works on reducing the number of polyps in patients with FAP.

A Study Comparing Two Anti-inflammatory Medications Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/281/studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome

Prevention
Prevention study for people with Lynch syndrome

The trial is enrolling people with Lynch syndrome. On average, the length of this study will last one year from the start of enrollment to completion. The study will measure  the effect of naproxen or aspirin on the immune cells in the gastrointestinal tract of people with Lynch syndrome. The trial will also evaluate any symptoms from the medications and any other changes of the colon and rectum.

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress

Prevention
People at high risk for prostate cancer due to an inherited mutation

This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.

Blood Markers of Early Pancreas Cancer

https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer

Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.

The purpose of this study is to try to find markers of early pancreatic cancer for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation

https://www.facingourrisk.org/research-clinical-trials/study/121/screening-for-pancreatic-cancer-in-patients-with-an-inherited-brca1-brca2-palb2-or-atm-mutation

Prevention

Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.

Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/109/blood-tests-to-measure-ovarian-reserves-in-women-with-a-brca-mutation-or-women-treated-for-early-stage-breast-cancer

Prevention

The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).

The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies. 

A Pancreatic Cancer Screening Study for High Risk Individuals

https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people

Prevention

The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.

Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer. 

Pancreatic Cancer Early Detection Program

https://www.facingourrisk.org/research-clinical-trials/study/20/pancreatic-cancer-early-detection

Prevention

This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals. 

Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + ATM
6 results

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT ID: NCT02478892 (https://classic.clinicaltrials.gov/show/NCT02478892)

MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT ID: NCT05608694 (https://classic.clinicaltrials.gov/show/NCT05608694)

Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT ID: NCT05129605 (https://classic.clinicaltrials.gov/show/NCT05129605)

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
NCT ID: NCT03250078 (https://classic.clinicaltrials.gov/show/NCT03250078)

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
NCT ID: NCT06151223 (https://classic.clinicaltrials.gov/show/NCT06151223)

Blood Markers of Early Pancreas Cancer
NCT ID: NCT03568630 (https://classic.clinicaltrials.gov/show/NCT03568630)

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.